N. Burchardi

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.

K. Weber, M. Rezai, P. Fasching, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.